Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Introduction In a previous observational study of 117 allogeneic hematopoietic stem cell transplant (Allo-HSCT) recipients, we found that 83 % of them achieved a specific humoral response after two doses (V1 and V2) of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine (Pfizer BioNTech). However, althou...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Bourgeois, Amandine, Coste-Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Imbert, Berthe-Marie, Drumel, Thomas, Mahé, Béatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Gastinne, Thomas, Tessoulin, Benoit, Jullien, Maxime, Vantyghem, Sophie, Bene, Marie C, Moreau, Philippe, Le Gouill, Steven, Chevallier, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701558/
http://dx.doi.org/10.1182/blood-2021-149178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701558/
http://dx.doi.org/10.1182/blood-2021-149178

Ejemplares similares